Home › Therapeutic areas › Immunology › Ulcerative Colitis
Ulcerative Colitis (7 companies)
Companies with an active program in Ulcerative Colitis.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Programs |
|---|---|---|---|---|---|
| EVMN | Evommune | DermatologyImmunology+1 | 1 | Phase 2 | 5 |
| PTN | Palatin Technologies | ImmunologyMetabolic+1 Rare | 1 | Phase 3 | 8 |
| PALI | Palisade Bio | Immunology | 1 | Phase 2 | 3 |
| PTGX | Protagonist Therapeutics | DermatologyHematology+2 Rare | 1 | Approved | 14 |
| SYRE | Spyre Therapeutics | DermatologyImmunology Rare | 6 | Phase 2 | 12 |
| VNDA | Vanda Pharmaceuticals | CardiovascularDermatology+6 Rare | 1 | Approved | 27 |
| XNCR | Xencor | ImmunologyNeurology+1 Rare | 2 | Approved | 28 |
No companies match.